Edition:
United States

Bayer AG (BAYGn.DE)

BAYGn.DE on Xetra

105.75EUR
3:31am EST
Change (% chg)

€0.65 (+0.62%)
Prev Close
€105.10
Open
€104.90
Day's High
€105.85
Day's Low
€104.70
Volume
161,251
Avg. Vol
1,856,765
52-wk High
€123.90
52-wk Low
€96.18

Chart for

About

Bayer AG is a life science company. The Company's segments are Pharmaceuticals, Consumer Health, Animal Health and Covestro. The Pharmaceuticals segment focuses on prescription products, especially for cardiology and women's healthcare, and on specialty therapeutics in the areas of oncology, hematology and ophthalmology. The... (more)

Overall

Beta: 0.98
Market Cap(Mil.): €86,912.21
Shares Outstanding(Mil.): 826.95
Dividend: 2.70
Yield (%): 2.57

Financials

  Industry Sector
P/E (TTM): -- 32.07 15.47
EPS (TTM): -- -- --
ROI: -- 15.07 33.71
ROE: -- 16.57 16.38

BRIEF-Bayer's Rivaroxaban Submitted To U.S. FDA For Approval

* RIVAROXABAN SUBMITTED TO U.S. FDA FOR APPROVAL IN PATIENTS WITH CORONARY AND/OR PERIPHERAL ARTERY DISEASE Source text - http://bit.ly/2B4uKdl Further company coverage: (Gdynia Newsroom)

Dec 11 2017

EU regulators to warn Bayer about Monsanto bid: source

BRUSSELS EU antitrust regulators are set to warn Bayer its planned purchase of U.S. seed maker Monsanto may hurt competition, a person familiar with the matter said on Friday, a move that would force Bayer to offer concessions to address the concerns.

Dec 08 2017

UPDATE 2-EU regulators to warn Bayer about Monsanto bid -source

BRUSSELS, Dec 8 EU antitrust regulators are set to warn Bayer its planned purchase of U.S. seed maker Monsanto may hurt competition, a person familiar with the matter said on Friday, a move that would force Bayer to offer concessions to address the concerns.

Dec 08 2017

EU regulators to warn Bayer about Monsanto bid - source

BRUSSELS, Dec 8 EU antitrust regulators are expected to warn Bayer in the coming weeks that its planned takeover of U.S. seed maker Monsanto may hurt competition, a person familiar with the matter said on Friday.

Dec 08 2017

SCOTUS declines to review $455 million award for Bayer in Dow patent fight

A Dow Chemical Co subsidiary reached a dead end on Monday in its bid to undo a ruling requiring it to pay rival Bayer AG $455 million plus interest for violating a patent licensing agreement related to herbicide-resistant soybean seeds.

Dec 05 2017

Jury orders Bayer, J&J to pay $28 million in Xarelto lawsuit

A Philadelphia state court jury on Tuesday ordered Bayer AG and Johnson & Johnson to pay $27.8 million to an Indiana couple over the drugmakers' failure to warn of internal bleeding risks from their blood thinner Xarelto.

Dec 05 2017

UPDATE 1-Jury orders Bayer, J&J to pay $28 million in Xarelto lawsuit

Dec 5 A Philadelphia state court jury on Tuesday ordered Bayer AG and Johnson & Johnson to pay $27.8 million to an Indiana couple over the drugmakers' failure to warn of internal bleeding risks from their blood thinner Xarelto.

Dec 05 2017

CORRECTED-Jury orders Bayer, J&J to pay $28 million in Xarelto lawsuit

Dec 5 A Philadelphia state court jury on Tuesday ordered Bayer AG and Johnson & Johnson to pay $27.8 million to an Indiana couple over the drugmakers' failure to warn of internal bleeding risks by its blockbuster drug Xarelto.

Dec 05 2017

BRIEF-Bayer: Updated Clinical Data From Larotrectinib Pediatric Phase I SCOUT Trial

* ‍UPDATED LAROTRECTINIB PEDIATRIC CLINICAL TRIAL DATA DEMONSTRATE CONTINUED DURABILITY OF RESPONSE IN TRK FUSION CANCERS​ Source text for Eikon: [ID:http://bit.ly/2iJSOeQ] Further company coverage: (Gdynia Newsroom)

Dec 04 2017

Bayer sticks to bone metastasis drug estimate after setback

BERLIN, Dec 1 Bayer is sticking to its peak sales estimate for bone metastasis drug Xofigo despite a setback in a late-stage drug trial, the head of the German group's pharmaceuticals unit said on Friday.

Dec 01 2017

Earnings vs. Estimates